Skip to main content
رجوع
FDMT logo

4D Molecular Therapeutics, Inc.

جودة البيانات: 100%
FDMT
NASDAQ Healthcare Biotechnology
KWD 9.88
▲ KWD 0.70 (7.63%)
القيمة السوقية: 504.39M
نطاق اليوم
KWD 9.34 KWD 10.24
نطاق 52 أسبوعًا
KWD 2.24 KWD 12.34
حجم التداول
883,954
متوسط 50 يوم / 200 يوم
KWD 8.71 / KWD 7.86
الإغلاق السابق
KWD 9.18

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -3.6 0.2
P/B 1.0 3.0
ROE % -27.6 3.6
Net Margin % -164.4 3.8
Rev Growth 5Y % 47.4 9.9
D/E 0.0 0.2

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 47.43% annually over 5 years — strong growth
Debt/Equity of 0.04 — conservative balance sheet
Negative free cash flow of -109.08M
PEG of 0.17 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 230147.16%
Capital efficient — spends only 0.63% of revenue on capex

النمو

Revenue Growth (5Y)
47.43%
Revenue (1Y)230194.59%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-27.57%
ROIC-22.70%
Net Margin-164.43%
Op. Margin-187.24%

الأمان

Debt / Equity
0.04
Current Ratio9.39
Interest Coverage0.00

التقييم

P/E Ratio
-3.60
Forward P/EN/A
P/B Ratio1.00
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 230194.59% Revenue Growth (3Y) 102.78%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 47.43% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 85.21M Net Income (TTM) -140.11M
ROE -27.57% ROA -24.72%
Gross Margin 91.05% Operating Margin -187.24%
Net Margin -164.43% Free Cash Flow (TTM) -109.08M
ROIC -22.70% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.04 Current Ratio 9.39
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.60 Forward P/E N/A
P/B Ratio 1.00 P/S Ratio 5.92
PEG Ratio 0.17 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -21.63%
Market Cap 504.39M Enterprise Value 465.56M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 85.21M 37,000.0 20.72M 3.13M 18.04M
Net Income -140.11M -160.87M -100.84M -107.49M -71.32M
EPS (Diluted) -2.42 -2.98 -2.58 -3.12 -2.46
Gross Profit 77.58M 37,000.0 -76.37M -77.12M -43.32M
Operating Income -159.55M -187.84M -112.87M -110.03M -71.33M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 566.71M 560.38M 339.89M 261.85M 353.49M
Total Liabilities 61.05M 49.78M 32.06M 30.51M 34.38M
Shareholders' Equity 505.66M 510.61M 307.83M 231.34M 319.11M
Total Debt 21.41M 24.61M 14.67M 16.12M 16.45M
Cash & Equivalents 60.24M 149.34M 249.11M 52.35M 153.00M
Current Assets 413.13M 434.93M 296.59M 220.51M 256.28M
Current Liabilities 43.99M 29.15M 18.95M 15.73M 16.34M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#44 of 148
55

النشاط الأخير

دخل Full Throttle
Mar 26, 2026